Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN®-Filo prime-boost Ebola vaccines: 6-month follow-up of a Phase I randomized trial in healthy adults

• Macaya Douoguih,
• Neil Goldstein,
• Stephan Bart,
• Kerstin Luhn,
• Wilbert Van Duijnhoven,
• Carla Truyers,
• Benoit Callendret

Affiliations

Macaya Douoguih

Janssen Infectious Diseases and Vaccines, Leiden, The Netherlands

Neil Goldstein

Janssen Infectious Diseases and Vaccines, Leiden, The Netherlands

Stephan Bart

Janssen Infectious Diseases and Vaccines, Leiden, The Netherlands

Kerstin Luhn

Janssen Infectious Diseases and Vaccines, Leiden, The Netherlands

Wilbert Van Duijnhoven

Janssen Infectious Diseases and Vaccines, Leiden, The Netherlands

Carla Truyers

Janssen Infectious Diseases and Vaccines, Leiden, The Netherlands

Benoit Callendret

Janssen Infectious Diseases and Vaccines, Leiden, The Netherlands